Lux Targets 2013 Refiling for Voclosporin in Uveitis
By Jennifer Boggs
Managing Editor
Managing Editor
Nearly two years after a complete response letter (CRL) delayed Lux Biosciences Inc.'s plans for oral voclosporin in noninfectious uveitis, the Jersey City, N.J.-based biotech completed patient enrollment in a new Phase III study aimed at addressing the FDA's request for additional clinical data.
